ICON Public Limited (NASDAQ:ICLR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of ICON Public Limited (NASDAQ:ICLR) have been given a consensus rating of “Moderate Buy” by the thirteen research firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $289.10.

A number of analysts have issued reports on the stock. Barclays cut their price objective on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. TD Cowen lowered their price objective on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. cut their target price on ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Leerink Partnrs upgraded ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Finally, Evercore ISI cut their price objective on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th.

ICON Public Stock Up 0.0 %

ICON Public stock opened at $209.71 on Thursday. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The stock has a market cap of $17.30 billion, a P/E ratio of 23.38, a P/E/G ratio of 1.54 and a beta of 1.21. The company’s 50-day moving average price is $212.42 and its two-hundred day moving average price is $276.66. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the company earned $3.10 earnings per share. As a group, analysts expect that ICON Public will post 13.42 EPS for the current year.

Institutional Investors Weigh In On ICON Public

A number of hedge funds and other institutional investors have recently bought and sold shares of ICLR. Ashton Thomas Private Wealth LLC bought a new position in ICON Public in the 2nd quarter valued at approximately $54,000. EverSource Wealth Advisors LLC increased its holdings in ICON Public by 39.2% in the second quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 111 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its holdings in ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after buying an additional 96 shares during the period. First Horizon Advisors Inc. lifted its holdings in ICON Public by 33.9% during the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after buying an additional 151 shares during the period. Finally, Crestwood Advisors Group LLC bought a new stake in shares of ICON Public in the 2nd quarter valued at about $288,000. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.